NEW DELHI – India’s business environment will remain highly challenging for innovative pharmaceutical firms, according to BMI Research. The report comes on the heels of the February U.S. Chamber International IP Index, which ranks India very low in intellectual property (IP) – 43rd among 45 countries that represent 90 percent of the global GDP.
NEW DELHI – India's business environment will remain highly challenging for innovative pharmaceutical firms, according to BMI Research. The report comes on the heels of the February U.S. Chamber International IP Index, which ranks India very low in intellectual property (IP) – 43rd among 45 countries that represent 90 percent of the global GDP.
HYDERABAD – India is registering healthy growth in pharma exports that are expected increase between 8 percent and 10 percent this year and the next, according to government estimates. It's powered by the country's strength as a generics manufacturing hub.
HYDERABAD, India – Smaller domestic and regional pharmaceutical and biotech companies are expanding their footprint in Asia while using the region as a launch pad to emerge as significant global players and to tap a growing ecosystem of biotech-related business. Many of those companies are in India, where policy initiatives and plenty of unmet needs have come together to encourage investment in the space.
NEW DELHI – A significant boost to India's Department of Biotechnology (DBT) in the country's latest budget has nevertheless left the domestic industry unimpressed and unenthused, with critics noting there are few new incentives to help the sector.
NEW DELHI – A significant boost to India’s Department of Biotechnology (DBT) in the country’s latest budget has nevertheless left the domestic industry unimpressed and unenthused, with critics noting there are few new incentives to help the sector.
NEW DELHI –In the wake of the death of a U.S. woman who had been infected with a drug-resistant bug in India, the country's drug regulator has ordered all companies involved in the drug supply chain system to strictly follow the country's guidelines in the Drugs and Cosmetics Act on the sale of medicines.
